GUD vs. BHC, THCX, CRON, ACB, TLRY, WEED, FIRE, OGI, EPI, and CPH
Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Bausch Health Companies (BHC), Hydropothecary (THCX), Cronos Group (CRON), Aurora Cannabis (ACB), Tilray Brands (TLRY), Canopy Growth (WEED), Supreme Cannabis (FIRE), Organigram (OGI), ESSA Pharma (EPI), and Cipher Pharmaceuticals (CPH). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Knight Therapeutics vs. Its Competitors
Bausch Health Companies (TSE:BHC) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.
Knight Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Knight Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
Knight Therapeutics has a consensus target price of C$7.15, indicating a potential upside of 17.41%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Bausch Health Companies.
Bausch Health Companies has a net margin of -1.88% compared to Knight Therapeutics' net margin of -8.81%. Bausch Health Companies' return on equity of 15.87% beat Knight Therapeutics' return on equity.
In the previous week, Knight Therapeutics' average media sentiment score of 0.68 beat Bausch Health Companies' score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the news media.
Knight Therapeutics received 76 more outperform votes than Bausch Health Companies when rated by MarketBeat users. Likewise, 73.72% of users gave Knight Therapeutics an outperform vote while only 63.93% of users gave Bausch Health Companies an outperform vote.
79.0% of Bausch Health Companies shares are held by institutional investors. Comparatively, 12.6% of Knight Therapeutics shares are held by institutional investors. 11.3% of Bausch Health Companies shares are held by insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Bausch Health Companies has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.
Summary
Knight Therapeutics beats Bausch Health Companies on 11 of the 18 factors compared between the two stocks.
Get Knight Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Knight Therapeutics Competitors List
Related Companies and Tools
This page (TSE:GUD) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy GUD Stock Free GUD Stock Alerts